Novartis Not Nervous About SGLT2 Threat To Entresto

Cardiovascular Blockbuster Closing In On $4-$5bn Sales Guidance

 
• By Kevin Grogan
frontrunner
Novartis expects Entresto to continue setting the pace in heart failure • Source: Alamy

More from Cardiovascular

More from Therapeutic Category